New Tests and Therapies Enable Personalized Cancer Treatment
Oncology is one of the most complex areas of medical care. Evernorth’s cancer consult service pairs subspecialists from leading cancer centers with community oncologists, improving access to the best ...
Read MoreUnderstanding Hemophilia
Breaking down the challenges, therapies and costs associated with hemophilia.
Read MoreTwo Ways to Assess the Holistic Value of Your Specialty Partner
Getting the most value out of your specialty drug management partner starts with asking the right questions.
Read MoreSimplifying medical benefit drug management complexities
An integrated approach to managing medically billed specialty drugs is key to optimizing cost savings and clinical outcomes.
Read MoreBiosimilar Approval and Adoption Challenges
Accelerating the progress of biosimilars is key to lowering drug costs and improving patient access to potentially life-saving therapies.
Read MoreUncovering behind-the-scenes challenges in bringing gene therapies to market
Patients getting access to expensive gene therapies is just one of the many challenges to bringing these sometimes life-saving drugs to market.
Read MoreThree specialty drug trends to prepare for: Biosimilars, gene and cell therapies, cancer drugs
Biosimilars, gene and cell therapies, and cancer drugs are filling the specialty pipeline. Here are some insights for each category to help you stay informed. This topic was the focus of a breakout...
Read MoreHow to have a data-driven discussion on gene and cellular therapies
As the number of approved gene and cellular therapies grows, you can start preparing your organization now by taking the right next steps.
Read MoreCopay Assistance Strategy Reduces Financial Burdens for Plans And Patients
Innovative solution provides $0 member cost for costly specialty drugs while reducing plans’ costs
Read MoreThe future of gene therapy
Recent research suggests that the number of gene therapies on the market is likely to increase to over 60 by 2030. As rapid advancements in the field continue, here is what plan sponsors can expect to...
Read More